Literature DB >> 8320173

Antimetastatic activity of polymeric RGDT peptides conjugated with poly(ethylene glycol).

I Saiki1, J Yoneda, Y Igarashi, M Aoki, N Kusunose, K Ono, I Azuma.   

Abstract

Polymeric peptides containing defined repetitive or cyclic structures of RGDT sequence, (RGDT)n (n = 1 to 11) and cyclo(RGDT)n (n = 2 to 4), at a dose of 500 micrograms exhibited an inhibitory effect on experimental lung metastasis upon co-injection with tumor cells and the magnitude of the effect increased in parallel with the increase of degree of repetition of the RGDT sequence. The conjugation of (RGDT)n (n = 1, 5, 11) with poly(ethylene glycol), PEG as a polymeric carrier led to enhanced inhibition of lung metastasis in proportion to the degree of RGDT sequence repetition and in a dose-dependent manner. Multiple i.v. administrations of PEG-(RGDT)11, at 2-day and 3-day intervals before the excision of primary tumors, effectively inhibited spontaneous lung metastasis by s.c. inoculation of tumors, whereas (RGDT)11 exhibited inhibition of lung metastasis only when given at 2-day intervals. This indicates that the conjugation of PEG with (RGDT)n allowed the prolongation of administration interval, implying a sustained inhibitory effect on tumor metastasis. In support of this supposition, a decrease in the arrest of radiolabeled tumor cells in the lungs was observed when PEG-(RGDT)11 was co-injected i.v. with tumor cells, or injected i.v. one day before tumor inoculation. In contrast, (RGDT)11 significantly inhibited the tumor cell arrest in the lungs only upon co-injection with tumor cells. We also noted that (RGDT)n, cyclo(RGDT)n and PEG-(RGDT)11 inhibited tumor cell invasion into Matrigel in a concentration-dependent manner and in proportion to the degree of RGDT sequence repetition, indicating that the peptide-mediated antimetastatic effect is partly associated with the anti-invasive potential. Thus, the conjugation of anti-cell adhesive and anti-metastatic RGDT peptide with PEG might provide a therapeutically promising basis for the prevention of cancer metastasis ("anti adhesion therapy").

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320173      PMCID: PMC5919174          DOI: 10.1111/j.1349-7006.1993.tb00176.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  27 in total

1.  Identification of a second active site in laminin for promotion of cell adhesion and migration and inhibition of in vivo melanoma lung colonization.

Authors:  H K Kleinman; J Graf; Y Iwamoto; M Sasaki; C S Schasteen; Y Yamada; G R Martin; F A Robey
Journal:  Arch Biochem Biophys       Date:  1989-07       Impact factor: 4.013

Review 2.  Basement membrane and the invasive activity of metastatic tumor cells.

Authors:  V P Terranova; E S Hujanen; G R Martin
Journal:  J Natl Cancer Inst       Date:  1986-08       Impact factor: 13.506

3.  YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation.

Authors:  Y Iwamoto; F A Robey; J Graf; M Sasaki; H K Kleinman; Y Yamada; G R Martin
Journal:  Science       Date:  1987-11-20       Impact factor: 47.728

4.  The selection and characterization of an invasive variant of the B16 melanoma.

Authors:  I R Hart
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

5.  Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules.

Authors:  I Saiki; J Iida; J Murata; R Ogawa; N Nishi; K Sugimura; S Tokura; I Azuma
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

6.  Effect of cyclic RGD peptide on cell adhesion and tumor metastasis.

Authors:  H Kumagai; M Tajima; Y Ueno; Y Giga-Hama; M Ohba
Journal:  Biochem Biophys Res Commun       Date:  1991-05-31       Impact factor: 3.575

Review 7.  'Seed and soil' revisited: mechanisms of site-specific metastasis.

Authors:  I R Hart
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

8.  The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.

Authors:  T K Gartner; J S Bennett
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

9.  Enhanced lymphatic delivery of mitomycin C conjugated with dextran.

Authors:  Y Takakura; S Matsumoto; M Hashida; H Sezaki
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

10.  Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene.

Authors:  A R Kornblihtt; K Umezawa; K Vibe-Pedersen; F E Baralle
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

View more
  1 in total

1.  Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.

Authors:  H Kobayashi; H Shinohara; J Gotoh; M Fujie; S Fujishiro; T Terao
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.